



In This Issue:

- ◆ Washoe County Quarterly Communicable Disease Statistics
- ◆ CDC HAN: Nationwide Voluntary Recall of All Products for Sterile Use from Compounding Pharmacy Located in Cedar Park, TX

August 15, 2013

Vol. 33, No. 16

Telephone (775) 328-2447

Fax (775) 328-3764

epicenter@washoecounty.us

WASHOE COUNTY HEALTH DISTRICT • P.O. BOX 11130 • RENO, NEVADA • 89520-0027 • (775) 328-2447



REPORTED CASES OF SELECTED COMMUNICABLE DISEASES WASHOE COUNTY 2nd Quarter: April - June 2013

To report a communicable
disease please call:
(775) 328-2447
or fax reports to:
(775) 328-3764

DISEASE	2 nd Quarter			Year to Date (Cumulative)		
	2011	2012	2013	2011	2012	2013
AIDS	3	5	6	8	11	7
Campylobacteriosis	17	11	11	28	17	19
Chlamydia	342	372	441	691	798	832
Cryptosporidiosis	1	3	4	2	4	3
E. coli O157:H7 (AKA:STEC 0157:H7)	0	0	3	0	0	3
Giardiasis	3	8	5	5	9	8
Gonorrhea	33	62	75	70	125	137
Haemophilus influenzae type b (Hib)	0	0	0	0	0	0
Hepatitis A (acute)	0	0	4*	0	0	4*
Hepatitis B (acute)	2	2	2	3	3	3
Hepatitis B (chronic)	9	13	10	15	26	23
Hepatitis C (acute)	2	0	2	3	2	4
Hepatitis C (Past or Present)	182	149	142	334	295	318
HIV not yet AIDS	3	4	3	7	11	11
Influenza (Type A, B, or unknown)	61	85	34	653	583	758
Measles	0	0	0	0	0	0
Meningitis, Viral or Aseptic	3	4	1	11	6	4
Meningococcal Disease	0	0	0	1	0	0
Pertussis (confirmed & Probable)	2	5	1	4	7	2
Pneumococcal Disease, Invasive	18	8	15	35	24	33
Rabies (bat)	1	4	0	1	4	0
Rotavirus	14	7	14	19	10	17
RSV	15	61	18	289	180	416
Salmonellosis	8	7	8	11	13	16
Shigellosis	0	0	0	0	0	0
Syphilis (Primary & Secondary)	3	5	2	4	7	7
Tuberculosis	4	3	2	4	5	3
West Nile Virus	0	0	0	0	0	0

*3 of 4 were associated with recent multi-state hepatitis A outbreak

Please share this document with all physicians/staff in your office/facility.

This is an official CDC HEALTH ADVISORY

Distributed via the CDC Health Alert Network
August 14, 2013, 16:00:00 ET (4:00:00 PM ET)
CDCHAN-00353

Nationwide Voluntary Recall of All Products for Sterile Use from Compounding Pharmacy located in Cedar Park, Texas

Summary:

The U.S. Food and Drug Administration (FDA) is alerting health care providers and patients of a voluntary nationwide recall of all products produced and distributed for sterile use by Specialty Compounding, LLC, Cedar Park, Texas. There have been recent reports of bacterial bloodstream infections potentially related to the company's calcium gluconate infusions.

CDC and the FDA are working with Texas state officials to determine the scope of the contamination. According to the FDA, information provided by the firm stated that the **recalled products (i.e., all products produced and distributed for sterile use by Specialty Compounding) were distributed directly to patients nationwide, with the exception of North Carolina, which received no products.** The full text of the recall is available on the FDA website at <http://www.fda.gov/Safety/Recalls/ucm364643.htm?source=govdelivery>. Also according to the FDA, information provided by the firm stated that recalled products were also distributed to hospitals and physician offices in Texas.

Background

The Texas Department of State Health Services has reported bacterial bloodstream infections in 15 patients from two Texas hospitals who received an infusion of calcium gluconate 2 grams in Sodium Chloride 0.9 percent for Injection, supplied by Specialty Compounding. According to Texas state officials, most infections were caused by *Rhodococcus equi* and are thought to be related to the infusions. Two of the 15 patients have died. CDC does not have information that the deaths are related to recalled product. Also according to Texas state officials, cultures from an intact sample of calcium gluconate compounded by Specialty Compounding show growth of bacteria that are consistent with *Rhodococcus* species. Isolates are being evaluated by CDC to confirm the identification.

Recommendations

All sterile use products produced and distributed by Specialty Compounding are being recalled, and none of these products should be used by patients or administered to patients. Facilities, health care providers, and patients who have received the products, should immediately discontinue use, quarantine the products, and return the products to Specialty Compounding (See <http://www.fda.gov/Safety/Recalls/ucm364643.htm?source=govdelivery>).

If patients who received recalled product are experiencing symptoms, especially fever, they should consult a physician.

Patients and physicians should report adverse reactions experienced with the use of any Specialty Compounding products to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax. Information on reporting adverse reactions can be found at:

- ◆ <https://www.accessdata.fda.gov/scripts/medwatch/>
- ◆ Download form at <http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm> or
- ◆ Call **1-800-332-1088** to request a reporting form, then complete and mail to the address on the pre-addressed form, or submit by fax to **1-800-FDA-0178**.